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Stress studiesAbstract The aim of the present work is to develop sensitive, simple, accurate, precise and cost
effective UV-spectrophotometric methods for the determination of sumatriptan succinate (STS),
an anti-migraine drug, in bulk and pharmaceutical dosage form; and also to monitor the degrada-
tion behavior of the drug under different ICH prescribed stress conditions. Two methods were
developed using different solvents, 0.1 M HCl (method A) and acetonitrile (method B). The calibra-
tion graphs are linear over the range of 0.2–6.0 lg ml1 in both the methods with a correlation coef-
ﬁcient (r) of 0.9999. The apparent molar absorptivity values are 7.59 · 104 and 7.81 · 104
l mol1 cm1, for method A and method B, respectively. The other optical characteristics such as
Sandell’s sensitivity, limit of detection (LOD) and limit of quantiﬁcation (LOQ) values are also
reported. The accuracy and precision of the methods were evaluated based on intra-day and
inter-day variations. The accuracy of the methods was further conﬁrmed by standard addition pro-
cedure. The degradation behavior of the drug was studied by subjecting STS to an acid and alkaline
hydrolysis, oxidative, thermal and UV degradation. This study indicated that STS was degraded in
alkaline medium and in oxidative condition. The proposed methods were successfully applied to the
determination of STS in tablets and the results obtained are comparable with the ofﬁcial method.
ª 2013 Production and hosting by Elsevier B.V. on behalf of University of Bahrain.1. Introduction
Triptans are a group of tryptamine-based drugs used in the
acute treatment of migraine headaches. Sumatriptan succinate
(Fig. 1) is one among them and is structurally related to the
neurotransmitter serotonin. Sumatriptan succinate (STS) is a
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Figure 1 Structure of sumatriptan succinate.
44 K.N. Prashanth et al.5-hydroxytryptamine (5-HT) receptor subtype (a member of
the 5-HT 1D family) having only a weak afﬁnity for 5-HT1A,
5-HT5A, and 5-HT7 receptors and chemically designated as
[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]-N-methylme-
thanesulfonamide hydrogen butanedioate (British Pharmaco-
poeia, 2009). STS acts by selectively binding to serotonin
type-1D receptors (serotonin agonist) and rapidly terminates
a migraine attack while eliminating associated symptoms such
as nausea, vomiting, and light and sound sensitivity (Conquer-
ing headache, 2003).
STS has ofﬁcial monographs in BP (British Pharmacopoeia,
2009) and EP (European Pharmacopoeia, 2005), which describe
liquid chromatographic methods for the assay of STS, and also
in USP (The United States Pharmacopoeia, 2004) which de-
scribes high-performance liquid chromatographic (HPLC)
method for its determination. Literature survey reveals that
few analytical methods have been published for the analysis
of STS in biological ﬂuids such as high-performance liquid
chromatography (HPLC) (Andrew et al., 1993; Ge et al.,
2004; Moira and Peter, 1996; Franklin et al., 1996) and liquid
chromatographic–mass spectrometry (Cheng et al., 1998). A
few methods are found in the literature for the determination
of STS in the bulk drug and in pharmaceutical preparations
and include high-performance liquid chromatography (HPLC)
(Avadhanulu et al., 1996; Shirsat et al., 1998; Sukhdev and
Ravi, 1997; Nagesh et al., 1997), ultra-performance liquid chro-
matography (UPLC) (Reddy et al., 2011), liquid chromatogra-
phy–mass spectrometry (LC–MS) (Xiaohui et al., 2001),
voltammetry (Sagar et al., 1992), capillary electrophoresis (Al-
tria and Filbey, 1993; Al Azzam et al., 2011), electrochemical
methods (Saeed et al., 2011; Mandana et al., 2011), visible spec-
trophotometry (Kalyanaramu and Raghubabu, 2010,
2011a,b,c; Fathima et al., 2012; Tipre and Vavia, 1999; Satyan-
arayana and Nageswara Rao, 2011) and UV-spectrophotome-
try (Prabahar et al., 2009; Pourmand et al., 2011; Gondalia and
Dharamsi, 2011; Trinath et al., 2010 Sagar et al., 2011).
Only two UV-spectrophotometric methods have been re-
ported for STS when it is present alone in tablets. A method
based on the measurement absorbance of the drug in water
at 220 nm has been reported (Prabahar et al., 2009) and the
method obeys Beer’s law in the 1–12 lg ml1 concentration
range. Measurement of the absorbance of aqueous solution
of drug at 282 nm in the range of 21–39 lg ml1 has served
as the basis of a method reported (Pourmand et al., 2011).
Simultaneous determination of STS and naproxen sodium
(NAP) by three different approaches is found in the literature.
The method involving determination of naproxen sodium and
STS using the ﬁrst derivative spectrophotometry at 241.0 and
236.0 nm over the concentration ranges of 0.5–3.5 lg ml1 for
both drugs has been described (Gondalia and Dharamsi,2011). Two UV-spectrophotometric methods (Trinath et al.,
2010) have been reported for the simultaneous determination
of STS and NAP in their combined dosage forms. First meth-
od is Q absorption ratio method using two wavelengths,
272 nm (kmax of NAP) and 284 nm (kmax of STS). The second
method is the ﬁrst order derivative technique. In this method
the zero crossing point of naproxen sodium was selected at
298 nm and for sumatriptan it was 335 nm. The solvent used
was methanol in both the methods and linearity range for Q
absorption ratio was 10–90 lg ml1 and for derivative method
it was 20–190 lg ml1. In another approach (Sagar et al.,
2011), STS and NAP were assayed by ﬁrst order derivative
method in which the zero crossing point of STS was at
329.8 nm and for NAP at 297.6 nm. The linearity was found
to be in the range of 3–18 lg ml1 for both the drugs when
methanol was used as solvent.
Most of the reported methods are often time consuming,
expensive, use multi or expensive reagents, cumbersome and
required expertise operational personnel as indicated in Ta-
ble 1. UV spectrophotometry, because of simplicity, reproduc-
ibility and speed and also it requires minimum solvent/reagent
system and less analysis time, is widely used for the assay of the
therapeutic compounds used as medications.
The UV-spectrophotometric technique is widely employed
in pharmaceutical analysis (Basavaiah et al., 2010, 2011; Raghu
et al., 2012; Walash et al., 2009; Hurtado et al., 2007). To study
the degradation behavior of the drug, susceptibility to oxida-
tion is one of the required tests. Also the acid or base hydroly-
sis, thermal and photolytic stability studies are required (ICH-
Q1A (R2), 2003). Even though a few UV-spectrophotometric
methods (Prabahar et al., 2009; Pourmand et al., 2011; Gonda-
lia and Dharamsi, 2011; Trinath et al., 2010; Sagar et al., 2011)
for the determination of STS were reported, none of them is sta-
bility-indicating. The reported two stability indicating methods
using HPLC (Sukhdev and Ravi, 1997) and micellar electroki-
netic chromatography (Al Azzam et al., 2011) require expensive
experimental set up and expertise personnel. Thus, two simple,
inexpensive, accurate, reproducible stability indicating UV
spectrophotometric methods for the determination of STS in
bulk drug and in tablets are developed. The methods are based
on the measurement of absorbance of STS solution in either
0.1 M HCl (method A) or acetonitrile (method B). The pro-
posed methods were validated as per ICH guidelines (ICH-
Q1A (R1), 2005). The developed methods were successfully ap-
plied to the quantiﬁcation of STS in its tablets without any
interference by the inactive ingredients.
2. Experimental
2.1. Apparatus
The Spectrophotometric measurements were carried out using
Shimadzu Pharmaspec 1700 UV/Visible spectrophotometer.
2.2. Materials
All chemicals used were of analytical reagent grade. Doubly-
distilled water was used to prepare solutions wherever re-
quired. Acetonitrile, hydrogen peroxide (H2O2), hydrochloric
acid and sodium hydroxide were purchased from Merck
(Mumbai, India). Sumatriptan succinate sample (purity
Table 1 Comparison of the proposed and the existing visible spectrophotometric methods.
Sl.
No.
Reagent/s kmax,
nm
Beer’s law range,
lg mL1 (e in
l mol1 cm1)
Remarks Ref.
1 Bromate–
bromide-
Multi step reaction, time
consuming
Satyanarayana and
Nageswara Rao (2011)
(a) methyl orange, 508 0.2–1.6 (1.90 · 105)
(b) indigo carmine 610 2.0–12.0 (2.71 · 104)
2 Folin-Ciocaltaeu
reagent
760 2.0–6.0 Multi step reaction Tipre and Vavia (1999)
3 Sodium
nitroprusside
acetaldehyde
552 4.0–20.0 (1.10 · 104) Requires rigid pH control Kalyanaramu and
Raghubabu (2011b)
4 (a) Brucine–
sodium
metaperiodate,
520 4.0–20.0 Multi step reaction Kalyanaramu and
Raghubabu (2011d)
(b) citric acid-
acetic anhydride
580 8.0–24.0
5 Folin reagent 455.6 16.0–48.0 (3.85 · 103) Strict pH control, time
consuming.
Kalyanaramu and
Raghubabu (2010)
6 Cobalt
thiocyanate
629.4 16.0–48.0 (3.97 · 103) Involves extraction step Kalyanaramu and
Raghubabu (2011a)
7 Tropaeolin-OOO 482.5 2.0–10.0 (2.08 · 104) Requires rigid pH control;
involves liquid–liquid
extraction
Kalyanaramu and
Raghubabu (2011c)
8 p-Chloranilic acid 520 20.0–184.0 (9.28 · 102) Less sensitive Fathima et al. (2012)
9 UV-absorption
measured in water.
220 1.0–12.0 No stress studies Prabahar et al. (2009)
10 UV-absorption
measured in water.
282 21.0–39.0 No stress studies Pourmand et al. (2011)
11 UV-absorption
measured in
Stress studies were performed,
highly sensitive.
Proposed methods
(a) 0.1 M HCl 226 7.59 · 104
(b) acetonitrile 228 7.81 · 104
UV-spectrophotometric determination of sumatriptan succinate 4599.5%) was kindly supplied by MSN laboratories, Hyderabad,
India. Two brands of tablets namely Suminat-25 and Suminat-
50 (Sun Pharmaceuticals Ltd., Sikkim, India) were purchased
from local commercial sources.
2.3. Reagents
Hydrochloric acid (1 M) was prepared by appropriate dilution
of concentrated acid (Sp. gr. 1.18) with water and further di-
luted to get 0.1 M HCl. A 5% solution of H2O2 was prepared
by diluting suitable volume of the commercially available re-
agent to 100 ml with water in a volumetric ﬂask. Sodium
hydroxide solution (1 M) was prepared by dissolving required
amount of the pellets in water.
2.4. Standard drug solution
Standard drug solutions of 10 lg ml1 STS in HCl (0.1 M) and
acetonitrile were prepared separately and used for assay in
method A and method B, respectively.
2.5. Procedures
2.5.1. Preparation of calibration curve
Into a series of 10 ml calibration ﬂasks, aliquots of standard
drug solution (0.2–6 ml of 10 lg ml1) equivalent to 0.2–
6.0 lg ml1 STS were accurately transferred and the volumewas made up to the mark with the solvent (0.1 M HCl in meth-
od A; acetonitrile in method B). The absorbance of each solu-
tion was then measured at 226 nm in method A and 228 nm in
method B, against the respective solvent.
In either case, calibration curve was prepared by plotting
the absorbance versus concentration of drug. The concentra-
tion of the unknown was read from the respective calibration
curve or computed from the regression equation derived using
the Beer’s law data.
2.5.2. Analysis of tablets
Twenty tablets from each brand (Suminat-25 and Suminat-50)
were weighed and crushed into a ﬁne powder using a Pestle
and Mortar. An amount of tablet powder equivalent to 10 mg
of STS was transferred into a 100 ml volumetric ﬂask. The con-
tent was shaken well with about 50 ml of the respective solvent
(0.1 M HCl in method A; acetonitrile in method B) for 20 min.
The mixture was diluted to the mark with the same solvent. It
was ﬁltered using Whatman No 42 ﬁlter paper. First 10 ml por-
tion of the ﬁltrate was discarded and a subsequent portion was
diluted to get a working concentration of 10 lg ml1 and sub-
jected to analysis following the procedures described earlier.
2.5.3. Procedure for the analysis of placebo blank and synthetic
mixture
A placebo blank containing starch (10 mg), acacia (15 mg), hy-
droxyl cellulose (10 mg), sodium citrate (10 mg), talc (20 mg),
Figure 2 Absorption spectra of STS in 0.1 M HCl (method A) and in acetonitrile (method B).
Table 2 Regression and analytical parameters.
Parameter Method A Method B
kmax, nm 226 228
Beer’s law limits (lg ml1) 0.2–6.0 0.2–6.0
Molar absorptivity (l mol1 cm1) 7.59 · 104 7.81 · 104
Sandell sensitivity* (lg cm2) 0.0054 0.0047
Limit of detection (lg ml1) 0.05 0.05
Limit of quantiﬁcation (lg ml1) 0.14 0.16
Regression equation, Y**
Intercept, (a) 0.0014 0.0252
Slope, (B) 0.1807 0.2108
Correlation coeﬃcient (r) 0.9999 0.9999
Standard deviation of intercept (Sa) 0.0165 0.0444
Standard deviation of slope (Sb) 0.0048 0.0178
* Limit of determination as the weight in lg per ml of solution,
which corresponds to an absorbance of A= 0.001 measured in a
cuvette of cross-sectional area 1 cm2 and l= 1 cm.
** Y= a+ bX, where Y is the absorbance, a is the intercept, b is
the slope and X is the concentration in lg ml1.
46 K.N. Prashanth et al.magnesium stearate (15 mg) and sodium alginate (10 mg) was
prepared by combining all components to form a homoge-
neous mixture. A 10 mg of the placebo blank was accurately
weighed and its solution was prepared as described under ‘tab-
lets’, and then subjected to analysis by following the general
procedure.
A synthetic mixture was prepared by adding an accurately
weighed 10 mg of STS to 10 mg of placebo mentioned above.
The extraction procedure for tablets was applied by taking re-
quired quantity of synthetic mixture to prepare 10 lg ml1
STS solutions. Three different volumes of the resulting syn-
thetic mixture solution (equivalent 1, 3 and 5 lg ml1 STS in
both the methods) were subjected to analysis by following
the respective general procedure.
2.5.4. Forced degradation study
A 4 ml aliquot of the standard 10 lg ml1 STS was taken (in
triplicate) in a 10 ml volumetric ﬂask and mixed with 5 ml of
1 M HCl (acid hydrolysis) or 1 M NaOH (alkaline hydrolysis)
or 5% H2O2 (oxidative degradation) and boiled for 2 h at
80 C on a hot water bath. The solution was cooled to room
temperature and diluted to the mark with either 0.1 M HCl
(method A) or acetonitrile (method B). In thermal degrada-
tion, solid drug was kept in Petri dish in an oven at 100 C
for 24 h. After cooling to room temperature, 10 mg of STS
was weighed and transferred to a 100 ml volumetric ﬂask, dis-
solved in and diluted up to the mark with the respective sol-
vent. For UV degradation study, suitable aliquot of the
stock solution (4 lg ml1) was exposed to UV radiation of
1.4 ﬂux intensity for 48 h in a UV chamber at a wavelength
of 226 nm in method A and 228 nm in method B. Finally,
the absorbance of all the resulting solutions (4 lg ml1 in
STS) obtained from acid and alkaline hydrolysis, oxidative
degradation, thermal and UV degradation of STS, was mea-sured at 226 and 228 nm in methods A and B, respectively,
against the respective solvent as blank in each case.
3. Results and discussion
3.1. Spectral characteristics
The STS solution in 0.1 M HCl (method A) and acetonitrile
(method B) showed absorption maximum at 226 and
228 nm, respectively. At these wavelengths 0.1 M HCl or ace-
tonitrile had insigniﬁcant absorbance. Therefore, further inves-
tigation for the analysis of STS was carried out at 226 nm
(method A) and 228 nm (method B). Fig. 2 represents the
UV-spectrophotometric determination of sumatriptan succinate 47absorption spectra of STS in 01 M HCl (method A) and aceto-
nitrile (method B) along with their respective blanks.
3.2. Method validation
3.2.1. Linearity, sensitivity, limits of detection and quantiﬁcation
A linear correlation was found between absorbance at kmax
and concentration of STS. The graphs are described by the
regression equation: Y= a+ bX (where Y= absorbance of
drug solution; a= intercept; b= slope and X= concentra-
tion of drug in lg ml1). The slope (b), intercept (a) and corre-
lation coefﬁcient (r) for each system were evaluated by using
the method of least squares Optical characteristics such as
Beer’s law limits, molar absorptivity and Sandell sensitivityTable 3 Evaluation of intra-day and inter-day precision and accur
Method STS taken (lg ml1) Intra-day (n= 7)
STS founda (lg ml1) % RS
Method A 1.00 1.01 0.60
3.00 2.98 1.26
5.00 5.06 0.71
Method B 1.00 1.02 0.91
3.00 3.06 1.35
5.00 4.97 1.04
a Mean value of ﬁve determinations.
b Relative standard deviation (%).
c Relative error (%).
Table 5 Robustness and ruggedness.
Method STS taken, lg ml1 Method robustness
wavelengths, nma RSD, % (n= 3)
Method A 1.00 0.98
3.00 1.24
5.00 1.31
Method B 1.00 1.42
3.00 0.77
5.00 1.13
a Wavelengths used were 225, 226 and 227 in method A and 227, 228 a
Table 4 Results of analysis of synthetic mixture by the proposed m
Method A
Synthetic mixture
lg ml1
Total found,
lg ml1
STS recovered*,
percent ± SD
1.00 1.01 101.4 ± 0.01
3.00 2.95 98.45 ± 0.03
5.00 5.10 102.1 ± 0.08values (ICH-Q1A (R2), 2003) of both the methods are calcu-
lated. The limit of detection (LOD) and limit of quantitation
(LOQ) are also calculated and all these data are presented in
Table 2. High values of molar absorptivity (e), low values of
Sandell sensitivity and LOD revealed that, the proposed meth-
ods are highly sensitive.
3.2.2. Precision and accuracy
To check the repeatability and system suitability of the pro-
posed methods, the assays described under ‘‘general proce-
dures’’ were repeated seven times within the day (intra-day
precision) and ﬁve times on ﬁve different days (inter-day preci-
sion). These assays were performed for three levels of analyte.
The percentage relative standard deviation (%RSD) valuesacy.
Inter-day (n= 5)
Db % REc STS founda (lg ml1) % RSDb % REc
0.99 1.02 0.90 1.73
0.52 2.97 1.21 0.91
1.13 5.07 1.08 1.37
1.98 1.03 1.10 2.62
2.11 3.07 1.58 2.24
0.52 5.06 0.71 1.16
Method ruggedness
Inter-analysts RSD, % (n= 3) Inter- cuvettes RSD, % (n= 3)
1.55 1.37
0.85 1.83
1.49 1.56
0.99 1.06
1.37 1.65
1.63 1.44
nd 229 in method B.
ethods.
Method B
Synthetic mixture
lg ml1
Total found,
lg ml1
STS recovered*,
percent ± SD
1.00 1.02 102.9 ± 0.01
3.00 3.10 103.5 ± 0.03
5.00 5.07 101.4 ± 0.14
Table 6 Results of analysis of tablets by the proposed methods.
Tablet brand name Label claim mg/tablet Found (percent of label claim ± SD)a
Reference method Proposed methods
Method A Method B
Suminat-25 25 99.78 ± 0.89 99.21 ± 0.95 101.1 ± 1.27
t= 0.98 t= 1.90
F= 1.14 F= 2.04
Suminat-50 50 100.6 ± 1.01 101.4 ± 1.34 102.1 ± 1.56
t= 1.01 t= 1.80
F= 1.76 F= 2.40
Tabulated t-value at the 95% conﬁdence level is 2.78.
Tabulated F-value at the 95% conﬁdence level is 6.39.
a Mean value of ﬁve determinations.
48 K.N. Prashanth et al.were 61.35% (intra-day) and 61.58% (inter-day) indicating
high precision of the methods. The accuracy of the methods
was evaluated as percentage relative error (RE) between the
measured mean concentrations and taken concentrations for
STS. Percent relative error (% RE) values of 62.62% demon-
strate the high accuracy of the proposed methods. The results
of this study are summarized in Table 3.
3.2.3. Selectivity
In the analysis of placebo blank, the absorbance value was
nearly the same as that for solvent in both the methods, sug-
gesting the non-interference by the inactive ingredients added
to prepare the placebo.
The effect of matrix in the assay of STS was checked using a
synthetic mixture. A 0.5 ml aliquot of the resulting STS extract
prepared by using synthetic mixture was assayed by following
the general procedure (n= 3), and yielded percentage recovery
values of 98.45–103.5 of STS (Table 4). These results pro-
nounced the non-interference from the matrix added to pre-
pare synthetic mixture.
3.2.4. Ruggedness and robustness
The robustness of the methods was evaluated by measuring the
absorbance at different wavelengths whereas the method rug-
gedness was performed by four different analysts and also
using three different cuvettes by a single analyst. Intermediate
precision values (% RSD) were in the range of 0.85–1.83%Table 7 Results of recovery study by standard addition method.
Tablets Studied Method A
STS in
tablets,
lg ml1
Pure STS
added,
lg ml1
Total
found,
lg ml1
Pure ST
recovere
Percent ±
Suminat-25 1.49 0.75 2.26 102.7 ±
1.49 1.50 3.01 101.3 ±
1.49 2.25 3.77 101.3 ±
Suminat-50 1.52 0.75 2.26 99.07 ±
1.52 1.50 3.00 98.67 ±
1.52 2.25 3.81 101.8 ±
Mean value of three determinations.indicating acceptable ruggedness. These results are presented
in Table 5.
3.2.5. Application to tablet analysis
Commercial STS tablets were analyzed using developed
methods and also by an ofﬁcial method (The United States
Pharmacopoeia, 2004). The ofﬁcial method describes chro-
matographic detection of STS using UV-detector at
282 nm. The results obtained were compared statistically
by Student’s t-test and the variance-ratio F-test (ICH-Q1A
(R1), 2005). The calculated t- and F- values did not exceed
the tabulated values of 2.77 (t) and 6.39 (F) at the 95%
conﬁdence level and for four degrees of freedom (Table 6),
indicating close similarity between the proposed methods
and the reference method with respect to accuracy and
precision.
3.2.6. Recovery study
To further ascertain the accuracy and reliability of the pro-
posed methods, recovery experiments were performed via stan-
dard-addition procedure. Pre-analyzed tablet powder was
spiked with pure STS at three different levels and the total
was found by the proposed methods. Each determination
was repeated three times. The percent recovery of pure STS
added was within the permissible limits indicating the absence
of inactive ingredients in the assay. These results are as illus-
trated in Table 7.Method B
S
d*,
SD
STS in
tablets,
lg ml1
Pure STS
added,
lg ml1
Total
found,
lg ml1
Pure STS
recovered*,
Percent ± SD
2.52 1.52 0.75 2.29 102.7 ± 1.56
1.42 1.52 1.50 3.01 99.33 ± 0.84
1.30 1.52 2.25 3.82 102.2 ± 1.66
0.82 1.53 0.75 2.29 101.3 ± 0.78
1.47 1.53 1.50 3.04 100.7 ± 1.49
1.08 1.53 2.25 3.82 101.8 ± 1.37
Figure 3 Acidic degradation. (a) (method A), (b) (method B).
Figure 4 Basic degradation. (a) (method A), (b) (method B).
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The stress studies of the drug were carried out by subjecting
STS to acid and alkali hydrolysis, dry heat treatment, UV-deg-
radation and hydrogen peroxide oxidation and later absorp-
tion spectra were recorded. The comparison of the UV
spectra of ‘‘stressed STS samples’’ with that of the ‘‘standardSTS solution’’ (Fig. 2) showed that STS does not undergo
degradation under acidic condition (Fig. 3). Similarly, STS
does not show any degradation under dry heat treatment
and when exposed to the UV radiation (Fig. 5). But, both
the absorption spectra of STS solutions in 0.1 M HCl and ace-
tonitrile treated with 1 M NaOH (Fig. 4) or hydrogen
Figure 5 Thermal degradation (a) (method A), (b) (method B) Photo degradation (c) (method A), (d) (method B).
50 K.N. Prashanth et al.peroxide showed that STS undergoes a signiﬁcant degradation
(Fig. 6).
4. Conclusions
In this study, the degradation behavior of STS was studied by
subjecting the drug to various stress conditions recommended
by ICH. The additional ﬁndings in this study show that the
drug undergoes an extensive degradation under alkaline and
oxidative conditions and stable to acidic, photolytic and ther-
mal stress conditions. The methods were validated for param-
eters like linearity, precision, accuracy, selectivity andruggedness. Application of these methods for the analysis of
STS in tablet dosage forms showed that there was no interfer-
ence of excipients in the determination. The methods are
advantageous over most of the reported methods in-terms of
sensitivity, simplicity, cost-effectiveness and experimental con-
ditions. The methods do not involve any tedious procedural
steps; do not require any extra reagents or longer analysis time
and a very simple instrument is required. This study is a typical
example of the development of a stability indicating assay,
established following the recommendations of ICH guidelines.
The methods can be used to determine the purity of the drug
available from various sources and in stability studies.
Figure 6 Peroxide degradation (a) (method A), (b) (method B).
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